Journal
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
Volume 24, Issue 2, Pages 331-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.hoc.2010.02.009
Keywords
Immunosuppression; Myelodysplastic syndrome; Tumor necrosis factor; IFN gamma
Categories
Funding
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL006106, ZIAHL006105, ZIAHL002342, ZIAHL006107, ZIAHL006088] Funding Source: NIH RePORTER
- Intramural NIH HHS [ZIA HL006106-02] Funding Source: Medline
Ask authors/readers for more resources
Laboratory evidence and clinical evidence suggest that some patients with myelodysplastic syndrome (MDS) have immunologically mediated disease. This article describes the laboratory evidence supporting a role for the immune system in the marrow failure of MDS and clinical trials using IST in these patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
